IL17A and COVID-19: Regarding specific treatment with biologic DMARDs, IL-6 receptor inhibitors were prescribed less frequently (lower prescription of tocilizumab), whereas IL-17A inhibitors were prescribed more frequently during COVID-19 (higher prescription of ixekizumab).